olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)
Phase 3RecruitingDevelopment Stage
Platinum-resistant Ovarian Cancer
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Aug 31, 2022 → Oct 1, 2026
About olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar) is a phase 3 stage product being developed by Genelux for Platinum-resistant Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05281471. Target conditions include Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Platinum-resistant Ovarian Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05281471 | Phase 3 | Recruiting |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer